Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment options for upper tract transitional-cell carcinoma

E K Seaman1, K M Slawin, M C Benson

  • 1J. Bentley Squier Urologic Clinic, Columbia-Presbyterian Medical Center, New York, New York.

The Urologic Clinics of North America
|May 1, 1993
PubMed
Summary

Nephroureterectomy with a bladder cuff is standard for upper urinary tract transitional-cell carcinoma. Renal-sparing approaches show promise for select low-grade tumors, potentially expanding roles for topical chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.

Prostate cancer and prostatic diseases·2014
Same author

Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era.

Urology·2008
Same author

Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.

International journal of impotence research·2008
Same author

Dyspareunia: an unusual presentation of leiomyoma of the bladder.

Reviews in urology·2006
Same author

Gene therapy for prostate cancer.

Reviews in urology·2006
Same author

Vaccine-based immunotherapy for prostate cancer.

Reviews in urology·2006

Area of Science:

  • Urology
  • Oncology

Background:

  • Transitional-cell carcinoma of the upper urinary tract (UTT-TCC) is typically treated with nephroureterectomy, including a bladder cuff.
  • The multifocal nature and recurrence potential of UTT-TCC necessitate aggressive treatment strategies.

Purpose of the Study:

  • To evaluate the feasibility and potential of renal-sparing approaches for UTT-TCC.
  • To explore the future role of topical chemotherapeutic agents in managing superficial UTT-TCC.

Main Methods:

  • Review of clinical outcomes for renal-sparing treatments of low-grade ureteral tumors.
  • Discussion of the implications of endoscopic renal-sparing therapies.

Main Results:

  • Good clinical results have been observed with renal-sparing treatments in specific cases of low-grade ureteral tumors.

Related Experiment Videos

  • These findings suggest the feasibility of conservative management in limited circumstances.

    • Conclusions:

    • While nephroureterectomy remains standard, renal-sparing approaches are viable for select UTT-TCC cases.
    • The increasing use of endoscopic techniques may enhance the role of topical chemotherapy for superficial UTT-TCC and bladder cancer.